ADAR1 Partners, LP bought $9.5M of Keros Therapeutics (KROS)

Executed Apr 9 2025, disclosed Apr 11 2025, 2 days later.

Value, as filed

$9.5M

934,258 sh across 5 lots

Executed

Apr 9 2025

the trade date, as filed

Disclosed

Apr 11 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+12.3%

+47.0% from execution

Over the 21 trading sessions from the disclosed entry session (Apr 11 2025), the stock returned +12.3% (delay-adjusted); from the execution session (Apr 9 2025), +47.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

AL ADAR1 Partners, LP 10% owner profile →

ADAR1 Partners, LP (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in KROS. Across 1 priced purchase filing, the average 21-session return was +47.0% from execution and +12.3% from disclosure (delay-adjusted; derived). The largest single filing was $9.5M of KROS (934,258 sh across 5 lots, as filed), executed Apr 9 2025.

The name

KROS KROS KROS · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→